The latest report by IMARC Group, titled “Anti-Tuberculosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028″. offers a comprehensive analysis of the industry, which comprises insights on the global anti-tuberculosis therapeutics market share. The global market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028.
Anti-tuberculosis therapeutics refer to the medical interventions and treatments designed to combat tuberculosis (TB), a contagious bacterial infection primarily affecting the lungs. These therapeutics encompass a range of pharmaceutical drugs and therapies aimed at diagnosing, treating, and preventing TB. The cornerstone of anti-tuberculosis therapeutics is a multidrug treatment regimen that typically includes antibiotics such as isoniazid, rifampicin, ethambutol, and pyrazinamide. These drugs work synergistically to target different aspects of the tuberculosis bacterium’s life cycle, reducing the risk of drug resistance. Anti-tuberculosis therapeutics may involve innovative diagnostic techniques, such as molecular assays and chest radiography, to identify TB cases accurately and swiftly. The goal of these therapeutics is to cure active TB infections, prevent its spread, and combat drug-resistant strains. It is essential to implement these therapies effectively, adhering to prescribed regimens to ensure treatment success and minimize the public health impact of tuberculosis.
Request Your Sample Report Now: https://www.imarcgroup.com/anti-tuberculosis-therapeutics-market/requestsample
Anti-Tuberculosis Therapeutics Market Trends and Drivers:
The persistent high prevalence of tuberculosis worldwide remains a primary driver. Regions like Africa, Asia, and Latin America have a substantial TB burden, necessitating a con stant demand for anti-tuberculosis therapeutics. Additionally, the emergence of drug-resistant tuberculosis strains, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), has compelled the development of new and more effective therapeutics, driving research and innovation. Other than this, increased awareness about TB symptoms and the importance of early diagnosis has led to more patients seeking treatment, contributing to market growth. Besides this, expanding access to healthcare services, particularly in low- and middle-income countries, ensures that more individuals receive anti-tuberculosis therapeutics, driving market expansion. In line with this, advances in diagnostic technologies for early and accurate TB detection have increased the effectiveness of treatment, stimulating market growth.
Report Segmentation:
The report has segmented the market into the following categories:
Disease Type Insights:
- Active TB
- Latent TB
- Others
Diagnosis and Treatment Insights:
- Diagnosis
- Blood Tests
- Imaging Tests
- Sputum Tests
- Others
- Treatment
- First-Line of Drugs
- Isoniazid
- Ethambutol
- Rifampin
- Others
- Second-Line of Drugs
- Thiacetazone
- Paraaminosalicyclic Acid (PAS)
- Others
- Others
- First-Line of Drugs
End User Insights:
- Hospitals
- Specialty Clinics
- Homecare
- Others
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- F Hoffmann-La Roche Ltd.
- Lannett Company Inc.
- Lupin Limited
- Macleods Pharmaceuticals Limited
- Otsuka Pharmaceutical Co. Ltd.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
Email: [email protected]
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
About Author
